<DOC>
	<DOCNO>NCT00479739</DOCNO>
	<brief_summary>To compare stable dose salmeterol/fluticasone propionate variable dose formoterol/budesonide dose adjust accord physician-guided self-management plan</brief_summary>
	<brief_title>CONCEPT : A 1-Year Comparison Of A Stable Dose Of SERETIDE速 Inhaler With An Adjustable Maintenance Dose Of SYMBICORT速 Inhaler . SERETIDE速 Inhaler Trademark GSK Group Companies . SYMBICORT速 Inhaler Trademark Astra Zeneca .</brief_title>
	<detailed_description>A randomised , double-blind , double-dummy , 52-week , parallel group study standard dose regimen salmeterol/fluticasone propionate combination 50/250mcg bid ( via DISKUS/ACCUHALER inhaler ) versus symptom-driven variable dose regimen formoterol/budesonide combination 6/200mcg ( via breath-actuated dry powder reservoir inhaler ) adult asthmatic</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Documented clinical history asthma Forced expiratory volume 1 second 60 % 90 % predict Using inhaled corticosteroid ( ICS ) dose equivalent 200 500 mcg daily beclomethasone ( BDP ) equivalent combine longacting beta2agonist ICS alone dose equivalent &gt; 500 1000mcg daily BDP daily Lower respiratory tract infection within 1 month study entry Use systemic corticosteroid within 1 month study entry Smoking history 10 pack year Changes regular asthma therapy within 12 week study entry Any significant disorder investigator 's opinion might put patient risk influence study outcome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>formoterol/budesonide</keyword>
	<keyword>exacerbation</keyword>
	<keyword>Salmeterol/fluticasone propionate</keyword>
	<keyword>adjustable maintenance dosing</keyword>
	<keyword>asthma control</keyword>
</DOC>